WO2013009143A9 - Marqueur pour le diagnostic d'une rétinopathie diabétique - Google Patents

Marqueur pour le diagnostic d'une rétinopathie diabétique Download PDF

Info

Publication number
WO2013009143A9
WO2013009143A9 PCT/KR2012/005622 KR2012005622W WO2013009143A9 WO 2013009143 A9 WO2013009143 A9 WO 2013009143A9 KR 2012005622 W KR2012005622 W KR 2012005622W WO 2013009143 A9 WO2013009143 A9 WO 2013009143A9
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic retinopathy
protein
expression level
gene
kit
Prior art date
Application number
PCT/KR2012/005622
Other languages
English (en)
Korean (ko)
Other versions
WO2013009143A3 (fr
WO2013009143A2 (fr
Inventor
김영수
유형곤
김경곤
김상진
유지영
Original Assignee
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교산학협력단 filed Critical 서울대학교산학협력단
Publication of WO2013009143A2 publication Critical patent/WO2013009143A2/fr
Publication of WO2013009143A9 publication Critical patent/WO2013009143A9/fr
Publication of WO2013009143A3 publication Critical patent/WO2013009143A3/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Definitions

  • the present invention is a composition, kit for diagnosing diabetic retinopathy, comprising a preparation for measuring the level of gene or protein that can be used for diagnosis and diagnosis of diabetic retinopathy patients, method for providing information for diagnosing diabetic retinopathy using the same and diabetes It relates to a method for diagnosing retinopathy.
  • Diabetes is a serious disease with increased blood sugar due to abnormalities in the production or use of insulin and accompanying various acute and chronic complications.
  • 9.6% (over 20 million people) of the population 20 years of age or older have diabetes, and an estimated 50 million pre-diabetes patients at high risk are estimated (2005 national diabetes facts in the United States. sheet).
  • $ 132 billion was spent on direct and indirect medical expenses related to diabetes.
  • diabetes Since diabetes has a long morbidity, it is accompanied by various complications of the whole system. Representative examples include cardiovascular disease, diabetes mellitus, diabetes neuropathy, and diabetic retinopathy. Among them, diabetic retinopathy (DR) occurs in over 60% of diabetic patients within 10 years of diabetic diagnosis and over 90% of diabetic patients in 20 years.
  • DR diabetic retinopathy
  • Diabetic retinopathy is a microangiopathy of diabetes characterized by changes in permeability of retinal vessels, vascular obstruction, ischemia, neovascularization, and thus fibrovascular proliferation.
  • Diabetic retinopathy is the largest cause of acquired blindness in adults, and in the United States, 12,000 to 24,000 people die from diabetes every year. In the United States, the prevalence of diabetic retinopathy is estimated to be about 40% of diabetic patients and 8% is reported to be a serious condition that can lead to blindness.
  • Diabetic retinopathy is divided into early non-proliferative diabetic retinopathy (NPDR) and late proliferative diabetic retinopathy (PDR) according to the degree of progression (FIG. 1).
  • NPDR non-proliferative diabetic retinopathy
  • PDR late proliferative diabetic retinopathy
  • Non-proliferative diabetic retinopathy is characterized by retinal bleeding, microaneurysm, exudate, retinal edema, etc. due to obstruction of the retinal capillaries and changes in permeability. have.
  • macular edema DME, diabetic macular edema
  • DME diabetic macular edema
  • Proliferative diabetic retinopathy is a stage in which neovascularization proliferates due to an ischemia condition following extensive vessel occlusion of the retina. This proliferation progresses from the retina to the vitreous and fibrovascular proliferation causes complications such as vitreous hemorrhage, tractional retinal detachment, and neovascular glaucoma, in which the retina falls from its original attachment site. This is the stage of blindness.
  • diabetic retinopathy has been mainly focused on biochemical and molecular biological studies of individual proteins in the vitreous.
  • proteomics study of diabetic retinopathy is a profiling (discovery) step of the vitreous protein bodies that identify proteins in patient vitreous by 2-DE and mass spcectrometry. Very little verification and validation studies have been conducted to determine whether these vitreous proteins are expressed in the blood or can be used as clinical biomarkers.
  • the present inventors have made diligent efforts to develop markers useful for early diagnosis of diabetic retinopathy. As a result, we have discovered a diabetic retinopathy-specific protein and using the expression pattern of the specific protein that increases or decreases in diabetic retinopathy. It was confirmed that can be easily diagnosed to complete the present invention.
  • One object of the present invention is a new diabetic retinopathy marker for early diagnosis of diabetic retinopathy, APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen)
  • APOC1 Apolipoprotein C1
  • APOB100 Apolipoprotein B100
  • APOC3 Polipoprotein C3
  • VTN Vitronectin
  • PLG Plasminogen
  • HRP Histidine-rich protein
  • AFM Afamin
  • CP ceruloplasmin
  • CFB Complement factor B
  • Still another object of the present invention is to provide a composition for diagnosing diabetic retinopathy comprising an agent for measuring the level of mRNA or protein thereof of at least one gene selected from the above markers.
  • Another object of the present invention to provide a kit for diagnosing diabetic retinopathy comprising the composition.
  • Still another object of the present invention is to provide a method for providing information necessary for diagnosing diabetic retinopathy by using the composition or kit for diagnosing diabetic retinopathy.
  • Another object of the present invention to provide a method for diagnosing diabetic retinopathy using the composition or kit for diagnosing diabetic retinopathy.
  • the present invention provides a marker for diagnosing diabetic retinopathy, and by measuring and comparing the expression level of a gene or a protein whose expression is increased or decreased in a diabetic retinopathy, the early diagnosis and the degree of disease of the diabetic retinopathy is significant. Can be predicted or identified.
  • the marker of the present invention enables a non-invasive diagnosis can be a simple and effective early diagnosis of diabetic retinopathy by blood, urine tests and the like.
  • 1 is an eye photograph of a patient with non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
  • FIG. 2 is a flow chart schematically showing the implementation process of the first to sixth embodiments.
  • FIG. 3 is a graph showing an ROC curve and an interactive plot of APOC1 according to Example 6.
  • FIG. 4 is a graph showing an ROC curve and an interactive plot of APOB100 according to Example 6.
  • FIG. 4 is a graph showing an ROC curve and an interactive plot of APOB100 according to Example 6.
  • FIG. 5 is a graph illustrating an ROC curve and an interactive plot of APOC3 according to Example 6.
  • FIG. 6 is a graph showing an ROC curve and an interactive plot of the VTN according to the sixth embodiment.
  • FIG. 7 is a graph illustrating an ROC curve and an interactive plot of PLG according to Example 6.
  • FIG. 8 is a graph illustrating an ROC curve and an interactive plot of HRP according to Example 6.
  • FIG 9 is a graph showing an ROC curve and an interactive plot of the AFM according to the sixth embodiment.
  • FIG. 10 is a graph showing an ROC curve and an interactive plot of CP according to Example 6.
  • FIG. 10 is a graph showing an ROC curve and an interactive plot of CP according to Example 6.
  • FIG. 11 is a graph illustrating an ROC curve and an interactive plot of CFB according to Example 6.
  • FIG. 12 is a graph illustrating an ROC curve and an interactive plot of AGP according to Example 6.
  • FIG. 12 is a graph illustrating an ROC curve and an interactive plot of AGP according to Example 6.
  • FIG. 13 is a graph illustrating an ROC curve and an interactive plot of PEDF according to Example 6.
  • the present invention is APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen), HRP (Histidine-rich protein),
  • APOC1 Apolipoprotein C1
  • APOB100 Apolipoprotein B100
  • APOC3 Apolipoprotein C3
  • VTN Vitronectin
  • PLG Plasminogen
  • HRP Histidine-rich protein
  • AFM Afamin
  • Ceruloplasmin CP
  • CFB Complement factor B
  • the term "diagnostic" means identifying the presence or characteristic of a pathological condition.
  • the diagnosis is to determine whether diabetic retinopathy develops. Preferably it is to determine whether the early stage of diabetic retinopathy non-proliferative diabetic retinopathy.
  • diagnosis marker refers to significant levels of gene expression or protein expression levels in individuals with non-proliferative diabetic retinopathy compared to normal controls (non-diabetic retinopathy) or proliferative diabetic retinopathy.
  • Organic biomolecules such as polypeptides or nucleic acids (eg, mRNA, etc.), lipids, glycolipids, glycoproteins, sugars (monosaccharides, disaccharides, oligosaccharides, etc.) and the like, which show increasing or decreasing aspects.
  • Markers for diagnosing diabetic retinopathy for the purposes of the present invention are APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen), HRP (Histidine-rich protein), AFM (Afamin) ), One or more selected from ceruloplasmin (CP) and complement factor B (CFB).
  • at least one selected from nine markers at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or at least nine may be used in combination.
  • the marker for diagnosing diabetic retinopathy may further include at least one selected from the group consisting of alpha-1 acid glycoprotein (AGP) or pigment epithelium-derived factor (PEDF).
  • AGP alpha-1 acid glycoprotein
  • PEDF pigment epithelium-derived factor
  • the marker may be AGP, PEDF alone, or a combination of AGP and PEDF.
  • one or more selected from the markers APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB, and AGP or PEDF or AGP and PEDF may be used as a diagnostic marker for diabetic retinopathy.
  • Diabetic retinopathy is divided into early stage of non-proliferative diabetic retinopathy (NPDR) and late stage proliferative diabetic retinopathy (PDR).
  • NPDR non-proliferative diabetic retinopathy
  • PDR proliferative diabetic retinopathy
  • Non-proliferative diabetic retinopathy is characterized by not developing blood vessels, and proliferative diabetic retinopathy is different in its mechanism, such as the development of blood vessels. Since non-proliferative diabetic retinopathy does not necessarily progress to proliferative diabetic retinopathy, a marker known as a diagnostic marker for proliferative diabetic retinopathy cannot necessarily be used as a diagnostic marker for non-proliferative diabetic retinopathy.
  • APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP, CFB, AGP and PEDF can be used as diagnostic markers for diabetic retinopathy.
  • biomarkers that overexpress or underexpress diabetic retinopathy by analyzing plasma samples from MH (macular hole), PDR (proliferative diabetic retinopathy), and NPDR (non-proliferative diabetic retinopathy) individuals Excavated.
  • samples of PDR and MH individuals were analyzed to identify PDR-specific candidate markers, and based on these, 11 NPDR-specific markers (APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP, CFB, AGP, and PEDF). ) was finally unearthed.
  • the plasma samples of the normal control group (non-diabetic retinopathy) and NPDR (non-proliferative diabetic retinopathy) subjects were analyzed to identify the 11 types of NPDR (non-proliferative diabetic retinopathy) identified above. The validity of the enemy marker was established.
  • the present invention is APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen), HRP (Histidine-rich protein), AFM (Afamin), CP (Ceruloplasmin) and CFB (Complement factor B) provides a composition for diagnosing diabetic retinopathy comprising an agent for measuring the mRNA or protein level of one or more genes selected from.
  • APOC1 Polipoprotein C1
  • APOB100 Polipoprotein B100
  • APOC3 Polipoprotein C3
  • APOC1 GeneBank Accession No. AAD02506, Uniprot: P02654
  • APOB100 GeneBank Accession No. AAB04636, Uniprot: P04114
  • APOC3 GeneBank Accession No. AAS68230, Uniprot: P02656
  • no association between APOC1, APOB100 and APOC3 with diabetic retinopathy is known at all.
  • VTN Vitronectin
  • PLG Plasminogen
  • HRP Histidine-rich protein
  • AFM (Afamin) is a protein involved in transport according to the gene ontology classification, and the genetic information can be found in GeneBank Accession No. AAI09021, Uniprot: P43652. However, the association of AFM with diabetic retinopathy is unknown at all.
  • CP ceruloplasmin
  • CFB Complement factor B
  • the APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB are all reduced in gene expression level or expression level of the protein in diabetic retinopathy compared to normal control (individual not diabetic retinopathy).
  • the diabetic retinopathy subject is preferably a non-proliferative diabetic retinopathy subject.
  • the composition may further comprise alpha-1 acid glycoprotein (AGP) and PEDF (AGP) to measure the mRNA or protein level of one or more genes selected from APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB.
  • AGP alpha-1 acid glycoprotein
  • PEDF PEDF
  • Pigment epithelium-derived factor may be a composition for diagnosing diabetic retinopathy comprising an agent for measuring the mRNA or protein level of one or more genes selected from.
  • Alpha-1 acid glycoprotein is an acute plasma alpha-globulin glycoprotein that is regulated by two polymorphic genes and, according to the gene ontology classification, is a protein involved in immune response and fibrin lysis. Is AGP (GeneBank Accession No. AAB33887, Uniprot: P02763). However, the association of AGP with diabetic retinopathy is unknown at all. AGP is characterized by an increase in the gene expression level or the expression level of the protein in the diabetic retinopathy subject compared to the normal control (individual non-diabetic retinopathy). The diabetic retinopathy subject is preferably a non-proliferative diabetic retinopathy subject.
  • PEDF Porture epithelium-derived factor
  • the genetic information is PEDF (GeneBank Accession No. AAK92491, Uniprot: P36955). However, no association between PEDF and diabetic retinopathy is known at all. PEDF is characterized by an increase in the gene expression level or expression level of the protein in diabetic retinopathy individuals compared to normal controls (individuals not diabetic retinopathy).
  • the diabetic retinopathy subject is preferably a non-proliferative diabetic retinopathy subject.
  • mRNA expression level measurement refers to measuring the amount of mRNA in the process of confirming the presence and expression of mRNA of the genes for diagnosing diabetic retinopathy in a biological sample in order to diagnose diabetic retinopathy.
  • Analytical methods for this purpose include reverse transcriptase (RT-PCR), competitive reverse transcriptase (RT) PCR, real-time reverse transcriptase (Real-time RT-PCR), RNase protection assay (RPA). assays, Northern blotting, DNA chips, etc., but are not limited thereto. Since nucleic acid information of genes according to the present invention is known to GeneBank et al., Those skilled in the art can design primer pairs or probes that specifically amplify specific regions of these genes based on the sequences.
  • protein expression level measurement refers to a process of confirming the presence and degree of expression of a protein expressed from a gene for diagnosing diabetic retinopathy in a biological sample to diagnose diabetic retinopathy. Protein expression level measurement is to determine the amount of protein using an antibody that specifically binds to the protein of the gene, preferably refers to measuring the protein expression level itself without using an antibody.
  • the protein expression level measurement or comparative analysis method is protein chip analysis, immunoassay, ligand binding assay, Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry (MALDI-TOF) analysis, Surface Enhanced Laser Desorption / SELDI-TOF Ionization Time of Flight Mass Spectrometry, radioimmunoassay, radioimmunoassay, oukteroni immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis, liquid phase chromatography-mass spectrometry liquid chromatography-Mass Spectrometry (LC-MS), liquid chromatography-Mass Spectrometry / Mass Spectrometry (LC-MS / MS), Western blotting, and enzyme linked immunosorbentassay (ELISA), but are not limited thereto.
  • MALDI-TOF Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry
  • diabetic retinopathy refers to a diabetic complication in which peripheral circulatory disorder occurs due to diabetes, which causes disorders in the microcirculation of the retina, resulting in decreased vision.
  • the diabetic retinopathy according to the invention is non-proliferative diabetic retinopathy.
  • the agent for measuring mRNA levels is specific for one or more genes selected from APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB and additionally one or more genes selected from AGP and PEDF.
  • primer pair includes primer pairs of all combinations of forward and reverse primers that recognize a target gene sequence, but preferably, a primer pair that provides an assay with specificity and sensitivity. to be. High specificity can be imparted when the nucleic acid sequence of the primer is a sequence that is inconsistent with the non-target sequence present in the sample so that only the target gene sequence containing the complementary primer binding site is amplified and does not cause nonspecific amplification. .
  • the term "probe” refers to a substance that can specifically bind to a target substance to be detected in a sample, and through the binding, a substance that can specifically confirm the presence of the target substance in the sample. it means.
  • the type of probe is a material commonly used in the art, but is not limited.
  • the probe may be a peptide nucleic acid (PNA), a locked nucleic acid (LNA), a peptide, a polypeptide, a protein, an RNA, or a DNA. It is PNA.
  • the probes include those derived from or similar to organisms or produced ex vivo as biomaterials, for example enzymes, proteins, antibodies, microorganisms, flora and fauna, organ cells, neurons, DNA, and RNA.
  • DNA may include cDNA, genomic DNA, oligonucleotides, RNA includes genomic RNA, mRNA, oligonucleotides, and examples of proteins may include antibodies, antigens, enzymes, peptides, and the like.
  • antisense refers to a nucleotide in which an antisense oligomer hybridizes with a target sequence in RNA by Watson-Crick base pairing, allowing formation of mRNA and RNA: oligomeric heterodimers typically within the target sequence.
  • the agent measuring the protein level is specific for at least one protein selected from APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB and at least one protein further selected from AGP and PEDF. It may include an antibody that binds to.
  • an antibody refers to a specific protein molecule directed against an antigenic site.
  • an antibody means an antibody that specifically binds to at least one protein selected from APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP, CFB, AGP, and PEDF.
  • Antibodies of the invention include all polyclonal antibodies, monoclonal antibodies and recombinant antibodies. Generating antibodies can be readily prepared using techniques well known in the art.
  • the antibodies of the present invention also include functional fragments of antibody molecules, as well as complete forms having two full length light chains and two full length heavy chains.
  • the functional fragment of an antibody molecule means the fragment which has at least antigen binding function, and includes Fab, F (ab '), F (ab') 2, Fv, etc.
  • the present invention provides a kit for diagnosing diabetic retinopathy comprising the composition for diagnosing diabetic retinopathy.
  • the kit may be an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or a multiple reaction monitoring (MRM) kit.
  • MRM multiple reaction monitoring
  • the diabetic retinopathy diagnostic kit may further include one or more other component compositions, solutions, or devices suitable for analytical methods.
  • the diagnostic kit may be a diagnostic kit comprising essential elements necessary to perform reverse transcriptase.
  • the reverse transcription polymerase kit contains each primer pair specific for the marker gene.
  • the primer is a nucleotide having a sequence specific to the nucleic acid sequence of each gene, and is about 7 bp to 50 bp in length, more preferably about 10 bp to 30 bp in length. It may also include primers specific for the nucleic acid sequence of the control gene.
  • reverse transcriptase kits include test tubes or other suitable containers, reaction buffers (pH and magnesium concentrations vary), enzymes such as deoxynucleotides (dNTPs), Taq-polymerase and reverse transcriptase, DNAse, RNAse inhibitor DEPC - May include DEPC-water, sterile water, and the like.
  • reaction buffers pH and magnesium concentrations vary
  • enzymes such as deoxynucleotides (dNTPs), Taq-polymerase and reverse transcriptase
  • DNAse DNAse
  • RNAse inhibitor DEPC - May include DEPC-water, sterile water, and the like.
  • the diagnostic kit may be a diagnostic kit comprising an essential element necessary to perform a DNA chip.
  • the DNA chip kit may include a substrate on which a cDNA or oligonucleotide corresponding to a gene or a fragment thereof is attached, and a reagent, a preparation, an enzyme, or the like for preparing a fluorescent probe.
  • the substrate may also comprise cDNA or oligonucleotide corresponding to the control gene or fragment thereof.
  • the diagnostic kit may be a diagnostic kit comprising essential elements necessary for performing an ELISA.
  • ELISA kits include antibodies specific for the protein. Antibodies are antibodies that have high specificity and affinity for each marker protein and have little cross-reactivity to other proteins. They are monoclonal antibodies, polyclonal antibodies, or recombinant antibodies.
  • the ELISA kit can also include antibodies specific for the control protein.
  • Other ELISA kits can bind reagents that can detect bound antibodies, such as labeled secondary antibodies, chromophores, enzymes (eg conjugated with the antibody) and substrates or antibodies thereof. Other materials and the like.
  • the present invention provides a method for providing information for diagnosing diabetic retinopathy using the diabetic retinopathy diagnostic composition or the diabetic retinopathy diagnostic kit.
  • the information providing method is APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen), HRP (Histidine) from biological samples isolated from patients with suspected diabetic retinopathy measuring the expression level or protein expression level of at least one gene selected from -rich protein, AFM (Afamin), ceruloplasmin (CP), and Complement factor B (CFB); And it may be a method of providing information for diagnosing diabetic retinopathy comprising comparing the expression level of the gene or the expression level of the protein with a normal control sample.
  • biological sample means a tissue, cell, whole blood, serum, plasma, saliva, cerebrospinal fluid or urine, or the like, in which the gene expression level or protein expression level is different due to the development of diabetic retinopathy. However, it is not limited thereto.
  • the APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB are characterized by a decrease in the expression level of the gene or protein expression compared to the normal control, diabetic retinopathy when the level is reduced Can diagnose and provide information.
  • the diabetic retinopathy is non-proliferative diabetic retinopathy.
  • the measuring and comparing step may further measure the expression level or protein expression level of one or more genes selected from the group consisting of Alpha-1 acid glycoprotein (AGP) and Pigment epithelium-derived factor (PEDF). And comparing.
  • AGP Alpha-1 acid glycoprotein
  • PEDF Pigment epithelium-derived factor
  • the AGP and PEDF has a characteristic that the expression level of the gene and the protein expression level is increased compared to the normal control, and when the level is increased can be diagnosed with diabetic retinopathy and provide information. At this time, the diabetic retinopathy is non-proliferative diabetic retinopathy.
  • the expression level of the gene of APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB or the expression level of the protein and the expression level of the gene of the individual sample of proliferative diabetic retinopathy or the expression level of the protein may further comprise determining that the reduction is non-proliferative diabetic retinopathy.
  • APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP, and CFB of the present invention reduce the gene or protein expression level in non-proliferative diabetic retinopathy, so it is a gene or protein of a proliferative diabetic retinopathy (PDR) individual.
  • PDR proliferative diabetic retinopathy
  • Reduction compared to the expression level can be determined as non-proliferative diabetic retinopathy (NPDR) during the progression of diabetic retinopathy.
  • NPDR non-proliferative diabetic retinopathy
  • At least one selected from the group consisting of AGP and PEDF as a complex marker increases the gene or protein expression level in non-proliferative diabetic retinopathy, and compares it with the gene or protein expression level of proliferative diabetic retinopathy (PDR) individuals. If increased, it can be determined as non-proliferative diabetic retinopathy (NPDR).
  • PDR proliferative diabetic retinopathy
  • the expression level of the gene of the present invention can measure or compare the mRNA expression level.
  • the mRNA expression level measurement or comparison may include, but is not limited to, reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, northern blotting or DNA chip.
  • the protein expression level of the present invention can be measured and compared using an antibody that specifically binds to the protein.
  • the antibody and the protein of interest in the biological sample form an antigen-antibody complex, and a method of detecting the antibody is used.
  • the term “antigen-antibody complex” means a combination of a protein antigen and an antibody that recognizes it to identify the presence or absence of the gene of interest in a biological sample.
  • the detection of the antigen-antibody complex can be detected using methods as known in the art, such as spectroscopic, photochemical, biochemical, immunochemical, electrical, absorbing, chemical and other methods.
  • the protein expression level measurement and comparison in the present invention is characterized by measuring and comparing the protein expression level itself without using an antibody.
  • the protein expression level measurement or comparative analysis methods include protein chip analysis, immunoassay, ligand binding assay, Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry (MALDI-TOF) analysis, SELDI-TOF (Sulface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radioimmunoassay, oukteroni immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis, liquid phase Liquid chromatography-mass spectrometry (LC-MS), liquid chromatography-mass spectrometry / mass spectrometry (LC-MS / MS), western blot, and enzyme linked immunosorbentassay (ELISA). .
  • MALDI-TOF Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry
  • SELDI-TOF Surface Enhanced
  • the LC-MRM method was used to measure and compare the protein expression levels of APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP, CFB, AGP or PEDF itself.
  • the protein in the biological sample was passed through the LC analysis column with a concentration gradient of 5% to 85% for 30 minutes with a solution of 5% distilled water, 95% acetonitrile, and 0.1% formic acid based on volume%. Since the resolution of a specific material may vary depending on the solution mixing ratio, a concentration gradient was performed, and the above range was selected for an optimal range for separating various proteins at the same time.
  • SIM Multiple reaction monitoring
  • MRM Multiple reaction monitoring
  • MRM Multiple reaction monitoring
  • MRM Multiple reaction monitoring
  • MRM Multiple reaction monitoring
  • MRM selects one ion from one broken ion one more time to source another MS in series. It is a method of using ions obtained from the collision after passing through it once more.
  • SIM there is a problem that the selected quantitative ion may interfere with the quantification when the selected quantitative ion is an ion that is also detected in plasma.
  • MRM even if ions with the same mass are broken once more, the molecular structure is different and tends to be differentiated. Can be obtained.
  • MRM mode in mass spectrometry, it was possible to simultaneously analyze the desired materials with better analytical sensitivity.
  • the present invention provides a combination of APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen), HRP (Histidine-rich protein), and AFM Measuring the expression level of one or more genes selected from the group consisting of Afamin), ceruloplasmin (CP) and Complement factor B (CFB) or expression levels of proteins; And it provides a method for diagnosing diabetic retinopathy comprising comparing the expression level of the gene or the expression level of the protein with a normal control sample.
  • the measuring and comparing step may further measure and compare the expression level of one or more genes selected from the group consisting of alpha-1 acid glycoprotein (AGP) and pigment epithelium-derived factor (PEDF) or the expression level of the protein. It may include a step.
  • AGP alpha-1 acid glycoprotein
  • PEDF pigment epithelium-derived factor
  • the present invention provides Alpha-1 acid glycoprotein (AGP), Pigment epithelium-derived factor (PEDF), APOC1 (Apolipoprotein C1), APOB100 (Apolipoprotein B100), APOC3 (Apolipoprotein C3), VTN (Vitronectin), PLG (Plasminogen), Hisidine-rich protein (HRP), AFM (Afamin), Ceruloplasmin (CP), and Complement factor B (CFB) are provided for use as a marker for diagnosing diabetic retinopathy.
  • AGP Alpha-1 acid glycoprotein
  • PEDF Pigment epithelium-derived factor
  • APOC1 Apolipoprotein C1
  • APOB100 Polipoprotein B100
  • APOC3 Apolipoprotein C3
  • VTN Vitronectin
  • PLG Plasminogen
  • HRP Hisidine-rich protein
  • AFM Afamin
  • Ceruloplasmin CP
  • CFB Complement factor B
  • MRM analysis of vitreous proteins in patients with proliferative diabetic retinopathy (PDR) and macular hole (MH) revealed MDR-specific candidate markers, which differ in expression.
  • NPDR non-proliferative diabetic retinopathy
  • Table 1 SEQ ID NO: Protein name Expression Gene Accession number Uniprot One Alpha-1 acid glycoprotein (AGP) Increased expression AAB33887 P02763 2 Pigment epithelium-derived factor (PEDF) Increased expression AAK92491 P36955 3 APOC1 (Apolipoprotein C1) Reduced expression AAD02506 P02654 4 APOB100 (Apolipoprotein B100) Reduced expression AAB04636 P04114 5 Apolipoprotein C3 (APOC3) Reduced expression AAS68230 P02656 6 Vitronectin (VTN) Reduced expression AAH05046 P04004 7 PLG (Plasminogen) Reduced expression AAA60113 P00747 8 Histidine-rich protein (HRP) Reduced expression AAI50592 P04196 9 AFM (Afamin) Reduced expression AAI09021 P43652 10 Ceruloplasmin (CP) Reduced expression AAF02483 P00450 11 Complement factor B (CFB) Reduced
  • Plasma samples from 45 patients with non-proliferative diabetic retinopathy (NPDR) early in diabetic retinopathy (NPDR) were obtained for LC-MS / MS test samples.
  • Clinical characteristics of the 45 patients with non-proliferative diabetic retinopathy (NPDR) and control patients are shown in Table 2 below. The three stages were mild, moderate and severe according to the progression of non-proliferative diabetic retinopathy.
  • NoDR Diabetic but no diabetic retinopathy
  • MI NPDR Mild NPDR
  • MO NPDR Moderate NPDR
  • SV NPDR Severe NPDR
  • Plasma samples were quantified using Bradford, of which 200 ⁇ g of plasma was taken, denatured into urea, reduced and alkylated with DTT and iodoacetic acid.
  • trypsin was treated at a ratio of 50: 1 (protein: trypsin, w / w) to make denatured proteins into peptides, and the peptides were desalted using C18 ZipTip and lyophilized. This was dissolved in solution A (95% distilled water, 5% acetonitrile, 0.1% formic acid) and spiked with 100 fmol of beta-galactosidase peptide, an internal standard, and analyzed by MRM. .
  • MS / MS analysis was performed on the proteins selected in the excavation study. Based on this, a representative peptide for each protein was selected (Q1 transition), and the highest intensity ion (Q3) was selected among fragmentation ions generated by electrically breaking the peptide. Two peptides per protein were selected and two fragmentation ions per peptide were selected to determine Q1 / Q3 as four transitions for one protein. Transitions were selected using the MRM-Initiated Detection and Sequencing (MIDAS) workflow program (MRMPliot, version 2.0, Appliedbiosystems, USA) for some transitions that were difficult to select due to low peaks. For transitions not captured by the MIDAS workflow program, the peptides were selected by selecting peptides with high observed numbers using the Peptide Atlas database.
  • MIDAS MRM-Initiated Detection and Sequencing
  • LC used MDLC nanoflow TempoLC of MDS.
  • C18 resin with a diameter of 3 ⁇ m and a pore size of 200 mm was directly filled using a fused sillica capillary column of 15 cm in length and 100 ⁇ m in diameter.
  • Peptide samples were injected by direct injection method, 1.0 ⁇ l was injected directly into the analitical column without passing through the trap column, and the flow rate was used as 400nl / min.
  • Mass spectrometry was monitored in MRM mode for transitions to selected proteins using 4000 QTrap instrument, Applied Biosystems' hybrid triple quadrupole / linear ion trap. Ion voltage was used at 2000 Volt and resolution at Quadruple 1 (Q1) and Quadruple 3 (Q3) was set in units. The dwell time for the transition was set to 20 milliseconds so that the total cycle time would be 2.5 seconds. Neubulizing gas was used in 5 units and heater temperature was set at 150 °C.
  • beta-galactosidase peptide (beta-galactosidase peptide, Transition 542.3 / 636.3) spiked in each sample was also monitored at the same time.
  • MS run time was run for 60 minutes in time synchronization with LC.
  • MS and LC were run using Analyst 2.1.2.
  • beta-galatosidase peptide (Transition 542.3 / 636.3) was used to quantify MRM at 8 concentration points of blank, 0.5, 1.0, 5.0, 10.0, 25.0, 50.0, and 100.0 fmol. Standard curve was determined.
  • the individual MRM results were generated by extracting ion ion chromatography (XIC) of the MRM transitions using MultiQuant (AppliedBiosystems, ver1.0), and the peak area of each transition was calculated and plotted again over time. . Normalize the area of each XIC peak to the XIC peak area of the beta-galatosidase peptide (Transition 542.3 / 636.3), an internal standard, and use this value to perform relative quantitative analysis for each protein.
  • ROC Receiveiver Operating Characteristic Curve and Interactive plot were prepared using MedCalc (MedCalc Software, Belgium, vesion 11.3.3) and ANOVA (Analysis of variance) statistical analysis was performed. Sigma Plot (Systat Software Inc, USA, version 10.1) was used for some plotting and t-test analysis.
  • FIGS. 3 to 11 are ROC curves and interactive plots of APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP, and CFB, respectively, and their expression is reduced compared to NoDR samples, resulting in non-proliferative diabetic retinopathy. It was confirmed that it can be used as a specific diagnostic marker.
  • 12 to 13 are ROC curves and interactive plots of AGP and PEDF, respectively, with increased expression compared to NoDR samples, respectively, with the addition of APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, CP and CFB. It was confirmed that it can be used as a diagnostic marker specific to non-proliferative diabetic retinopathy.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une composition et une trousse comprenant un agent pour la mesure d'un niveau d'un gène ou d'une protéine qui peuvent être utilisés pour diagnostiquer et déterminer la progression d'un patient atteint d'une rétinopathie diabétique, pour le diagnostic d'une rétinopathie diabétique, un procédé pour fournir des informations pour le diagnostic d'une rétinopathie diabétique, et une méthode de diagnostic d'une rétinopathie diabétique à l'aide de la composition et de la trousse.
PCT/KR2012/005622 2011-07-14 2012-07-13 Marqueur pour le diagnostic d'une rétinopathie diabétique WO2013009143A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110070122A KR20130009204A (ko) 2011-07-14 2011-07-14 당뇨망막병증 진단용 마커 및 이의 용도
KR10-2011-0070122 2011-07-14

Publications (3)

Publication Number Publication Date
WO2013009143A2 WO2013009143A2 (fr) 2013-01-17
WO2013009143A9 true WO2013009143A9 (fr) 2013-03-28
WO2013009143A3 WO2013009143A3 (fr) 2013-05-30

Family

ID=47506750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/005622 WO2013009143A2 (fr) 2011-07-14 2012-07-13 Marqueur pour le diagnostic d'une rétinopathie diabétique

Country Status (2)

Country Link
KR (1) KR20130009204A (fr)
WO (1) WO2013009143A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020179953A1 (fr) * 2019-03-07 2020-09-10 (주)레티마크 Marqueur composite radioactif pour le diagnostic d'un mélanome malin et utilisation de ce dernier
KR102309635B1 (ko) * 2019-03-07 2021-10-06 (주)레티마크 당뇨망막병증 진단용 복합 마커 및 이의 용도
WO2020189821A1 (fr) * 2019-03-20 2020-09-24 (주)레티마크 Marqueur sanguin pour diagnostiquer les principales maladies responsables de cécité, et procédé de diagnostic les utilisant
RU2765437C1 (ru) * 2021-08-17 2022-01-31 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ определения уровня экспрессии гена, кодирующего PEDF, в тканях глаза кролика Oryctolagus cuniculus и набор для его определения

Also Published As

Publication number Publication date
WO2013009143A3 (fr) 2013-05-30
KR20130009204A (ko) 2013-01-23
WO2013009143A2 (fr) 2013-01-17

Similar Documents

Publication Publication Date Title
WO2013009146A2 (fr) Marqueur pour le diagnostic d'une rétinopathie diabétique
EP2971285B1 (fr) Biomarqueurs sanguins prédisant la persistance d'un dysfonctionnement cognitif après commotion
WO2018097646A1 (fr) Composition de diagnostic de maladies
WO2021150011A1 (fr) Biomarqueur pour le diagnostic précoce du diabète ou des complications diabétiques, et utilisation associée
WO2013009143A2 (fr) Marqueur pour le diagnostic d'une rétinopathie diabétique
WO2006098464A1 (fr) Méthode pour diagnostiquer le cancer de la prostate
WO2013103226A1 (fr) Marqueur pour le diagnostic précoce de la rétinopathie diabétique et son utilisation
KR100925147B1 (ko) 폐암 진단용 마커
WO2020256526A1 (fr) Biomarqueur exosomal urinaire permettant de diagnostiquer un rejet médié par anticorps après une transplantation rénale ou de prédire le pronostic d'un patient après une transplantation rénale
WO2016093567A1 (fr) Biomarqueur pour le diagnostic de l'hépatome et son utilisation
WO2010085124A2 (fr) Marqueur pour le diagnostic du cancer du foie, la prédiction de sa récurrence et la prédiction de survie associée, trousse comprenant ledit marqueur et prédiction du pronostic chez des patients atteints d'un cancer du foie faisant appel audit marqueur
WO2022203372A1 (fr) Composition de biomarqueur pour le diagnostic de la dépression, et son utilisation
WO2022203314A2 (fr) Composition pour le diagnostic différentiel d'une tumeur maligne des gaines nerveuses périphériques
WO2021071219A1 (fr) Biomarqueur pour le diagnostic de maladies neurodégénératives
WO2020091222A1 (fr) Protéines de biomarqueurs pour le diagnostic de la maladie d'alzheimer et leurs utilisations
WO2013103225A1 (fr) Marqueur pour le diagnostic précoce de la rétinopathie diabétique et son utilisation
WO2014003343A1 (fr) Marqueur pour le diagnostic d'une rétinopathie diabétique et son utilisation
KR102009519B1 (ko) 당뇨망막병증 진단용 마커 및 이의 용도
KR101343285B1 (ko) 당뇨망막병증의 조기 진단용 마커 및 이의 용도
KR20200028320A (ko) 알츠하이머병 질환 탐지용 바이오마커 및 이를 이용한 알츠하이머병 질환 진단
WO2016093629A1 (fr) Biomarqueur pour prédire une réponse médicamenteuse ciblant un hépatome et son utilisation
KR102717871B1 (ko) 자폐 스펙트럼 장애 진단용 조성물, 키트 및 방법
KR101795689B1 (ko) 혈관 협착 질환 진단용 마커 및 이의 용도
WO2021172923A1 (fr) Composition pour le diagnostic du cancer
WO2022186486A1 (fr) Utilisation de la chaîne alpha-4 de la tropomyosine et de la chaîne bêta de la glycoprotéine ib plaquettaire pour le diagnostic de la maladie d'alzheimer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12810761

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct app. not ent. europ. phase

Ref document number: 12810761

Country of ref document: EP

Kind code of ref document: A2